{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T11:25:48Z","timestamp":1783077948390,"version":"3.54.6"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Lukang Christian Hospital","award":["Y_115_0038"],"award-info":[{"award-number":["Y_115_0038"]}]},{"name":"Taiwan Ministry of Health and Welfare Clinical Trial Center","award":["MOHW113-TDU-B-212-114009"],"award-info":[{"award-number":["MOHW113-TDU-B-212-114009"]}]},{"DOI":"10.13039\/501100004391","name":"China Medical University Hospital","doi-asserted-by":"crossref","award":["DMR-111-105; DMR-112-087; DMR-113-009; DMR-113-156; DMR-114-046; DMR-114-139; DMR-115-161"],"award-info":[{"award-number":["DMR-111-105; DMR-112-087; DMR-113-009; DMR-113-156; DMR-114-046; DMR-114-139; DMR-115-161"]}],"id":[{"id":"10.13039\/501100004391","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pyogenic liver abscess (PLA) is a life-threatening infection rising in East Asia, especially among patients with type 2 diabetes. Although SGLT2 inhibitors improve glycemic control and offer extraglycemic benefits, their effect on PLA risk is unknown. Using Taiwan\u2019s National Health Insurance Research Database, we conducted a nationwide retrospective cohort study of adults with T2DM. After 1:1 propensity score matching, 258,800 SGLT2i users and 258,800 non-users were included. The primary outcome was incident PLA. Incidence rates were calculated per 1,000 person-years, and adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) were estimated using multivariable Cox proportional hazards models. Additional analyses included subgroup analyses with interaction testing, a time-dependent Cox model, a competing-risks model, and a negative-control outcome analysis using fracture. During follow-up, 1,275 PLA events were identified. The incidence rate of PLA was 0.75 per 1,000 person-years in SGLT2i users and 0.83 per 1,000 person-years in non-users. In the primary multivariable Cox model, SGLT2i use was associated with a lower risk of PLA compared with nonuse (aHR, 0.88; 95% CI, 0.79\u20130.99). This inverse association was generally consistent across most subgroups. In the time-dependent analysis, SGLT2i use remained associated with a lower PLA risk (aHR, 0.72; 95% CI, 0.64\u20130.81). SGLT2i therapy was independently associated with reduced PLA risk in T2DM patients, particularly with prolonged exposure. These findings suggest an inverse association between SGLT2i use and the risk of pyogenic liver abscess in patients with T2DM.<\/jats:p>","DOI":"10.1038\/s41598-026-50136-7","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T09:07:32Z","timestamp":1777712852000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sodium-glucose cotransporter-2 inhibitors and the risk for liver abscess in patients with type 2 diabetes mellitus: a nationwide retrospective cohort study"],"prefix":"10.1038","volume":"16","author":[{"given":"Wu-Lung","family":"Chuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruey-Hwang","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Li","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Der-Yang","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang-Hsi","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"issue":"10","key":"50136_CR1","first-page":"1182","volume":"15","author":"A Onder","year":"2011","unstructured":"Onder, A. et al. Surgical management of pyogenic liver abscess. Eur. Rev. Med. Pharmacol. Sci. 15 (10), 1182\u20131186 (2011).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"8","key":"50136_CR2","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.dld.2008.01.016","volume":"40","author":"G Ferraioli","year":"2008","unstructured":"Ferraioli, G. et al. Percutaneous and surgical treatment of pyogenic liver abscesses: observation over a 21-year period in 148 patients. Dig. Liver Dis. 40 (8), 690\u2013696 (2008).","journal-title":"Dig. Liver Dis."},{"key":"50136_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002489","author":"C-C Sung","year":"2016","unstructured":"Sung, C.-C. et al. Pyogenic liver abscess is associated with increased risk of acute kidney injury: A nationwide population-based cohort study.. Medicine https:\/\/doi.org\/10.1097\/MD.0000000000002489 (2016).","journal-title":"Medicine"},{"issue":"1","key":"50136_CR4","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1186\/s12879-021-06649-9","volume":"21","author":"JA Losie","year":"2021","unstructured":"Losie, J. A. et al. Epidemiology and risk factors for pyogenic liver abscess in the Calgary Health Zone revisited: A population-based study. BMC Infect. Dis. 21(1), 939 (2021).","journal-title":"BMC Infect. Dis."},{"issue":"10","key":"50136_CR5","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.3201\/eid1410.071254","volume":"14","author":"FC Tsai","year":"2008","unstructured":"Tsai, F. C. et al. Pyogenic liver abscess as endemic disease, Taiwan. Emerg. Infect. Dis. 14 (10), 1592\u20131600 (2008).","journal-title":"Emerg. Infect. Dis."},{"key":"50136_CR6","doi-asserted-by":"publisher","first-page":"38587","DOI":"10.1038\/srep38587","volume":"6","author":"Y Qian","year":"2016","unstructured":"Qian, Y. et al. A retrospective study of pyogenic liver abscess focusing on Klebsiella pneumoniae as a primary pathogen in China from 1994 to 2015. Sci. Rep. 6, 38587 (2016).","journal-title":"Sci. Rep."},{"key":"50136_CR7","volume":"8","author":"T-Y Wang","year":"2021","unstructured":"Wang, T.-Y. et al. Pyogenic liver abscess risk in patients with newly diagnosed type 2 diabetes mellitus: A nationwide, population-based cohort study.. Front. Med. 8, 2021 (2021).","journal-title":"Front. Med."},{"issue":"1","key":"50136_CR8","doi-asserted-by":"publisher","first-page":"7922","DOI":"10.1038\/s41598-023-34889-z","volume":"13","author":"JL Wang","year":"2023","unstructured":"Wang, J. L. et al. Diabetes and obesity and risk of pyogenic liver abscess. Sci. Rep. 13 (1), 7922 (2023).","journal-title":"Sci. Rep."},{"key":"50136_CR9","unstructured":"Padda, I. S. & Parmar, M. A. M. Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors. 2023 2023 Jun 3 2025 May 29]; Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK576405\/"},{"issue":"1","key":"50136_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12933-020-01071-y","volume":"19","author":"L Ni","year":"2020","unstructured":"Ni, L. et al. SGLT2i: Beyond the glucose-lowering effect. Cardiovasc. Diabetol. 19(1), 98 (2020).","journal-title":"Cardiovasc. Diabetol."},{"issue":"5","key":"50136_CR11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41581-022-00535-6","volume":"18","author":"AB van der Aart","year":"2022","unstructured":"van der Aart, A. B., de Boer, R. A. & Heerspink, H. J. L. Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nat. Rev. Nephrol. 18 (5), 294\u2013306 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"50136_CR12","first-page":"212262","volume":"3","author":"JJ Neumiller","year":"2014","unstructured":"Neumiller, J. J. Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Drugs Context. 3, 212262 (2014).","journal-title":"Drugs Context"},{"key":"50136_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001956","author":"SC Shao","year":"2020","unstructured":"Shao, S. C. et al. SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: An umbrella review of systematic reviews.. BMJ Open Diabetes Res. Care https:\/\/doi.org\/10.1136\/bmjdrc-2020-001956 (2020).","journal-title":"BMJ Open Diabetes Res. Care"},{"issue":"5","key":"50136_CR14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","volume":"55","author":"R Puckrin","year":"2018","unstructured":"Puckrin, R. et al. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 55 (5), 503\u2013514 (2018).","journal-title":"Acta Diabetol."},{"issue":"7","key":"50136_CR15","doi-asserted-by":"publisher","first-page":"134","DOI":"10.31083\/j.fbl2807134","volume":"28","author":"R Xu","year":"2023","unstructured":"Xu, R. et al. SGLT-2 inhibitors for non-alcoholic fatty liver disease: A review. Front. Biosci. (Landmark Ed) 28(7), 134 (2023).","journal-title":"Front. Biosci. (Landmark Ed)"},{"key":"50136_CR16","doi-asserted-by":"publisher","first-page":"675345","DOI":"10.3389\/fmed.2021.675345","volume":"8","author":"TY Wang","year":"2021","unstructured":"Wang, T. Y. et al. Pyogenic Liver Abscess Risk in Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Nationwide, Population-Based Cohort Study. Front. Med. (Lausanne). 8, 675345 (2021).","journal-title":"Front. Med. (Lausanne)"},{"issue":"1","key":"50136_CR17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3945\/an.115.010207","volume":"7","author":"CJ Andersen","year":"2016","unstructured":"Andersen, C. J., Murphy, K. E. & Fernandez, M. L. Impact of obesity and metabolic syndrome on immunity. Adv. Nutr. 7 (1), 66\u201375 (2016).","journal-title":"Adv. Nutr."},{"key":"50136_CR18","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1991.00400080059010","author":"D-L cheng","year":"1991","unstructured":"cheng, D.-L. Septic metastatic lesions of pyogenic liver abscess.. Arch. Intern. Med. https:\/\/doi.org\/10.1001\/archinte.1991.00400080059010 (1991).","journal-title":"Arch. Intern. Med."},{"issue":"1","key":"50136_CR19","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12876-018-0875-y","volume":"18","author":"W Li","year":"2018","unstructured":"Li, W. et al. A comparison of pyogenic liver abscess in patients with or without diabetes: A retrospective study of 246 cases. BMC Gastroenterol. 18(1), 144 (2018).","journal-title":"BMC Gastroenterol."},{"issue":"45","key":"50136_CR20","doi-asserted-by":"publisher","first-page":"16795","DOI":"10.3748\/wjg.v20.i45.16795","volume":"20","author":"V Giannelli","year":"2014","unstructured":"Giannelli, V. et al. Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis. World J. Gastroenterol. 20 (45), 16795\u201316810 (2014).","journal-title":"World J. Gastroenterol."},{"issue":"11","key":"50136_CR21","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S1473-3099(12)70205-0","volume":"12","author":"LK Siu","year":"2012","unstructured":"Siu, L. K. et al. Klebsiella pneumoniae liver abscess: a new invasive syndrome. Lancet. Infect. Dis. 12 (11), 881\u2013887 (2012).","journal-title":"Lancet. Infect. Dis"},{"issue":"1","key":"50136_CR22","doi-asserted-by":"publisher","first-page":"11511","DOI":"10.1038\/s41598-019-48017-3","volume":"9","author":"JS Liu","year":"2019","unstructured":"Liu, J. S. et al. Aspirin use is associated with reduced risk for recurrence of pyogenic liver abscess: a propensity score analysis. Sci. Rep. 9 (1), 11511 (2019).","journal-title":"Sci. Rep."},{"issue":"1","key":"50136_CR23","doi-asserted-by":"publisher","first-page":"21329","DOI":"10.1038\/s41598-020-78442-8","volume":"10","author":"CH Tai","year":"2020","unstructured":"Tai, C. H. et al. The impact of aspirin on Klebsiella pneumoniae liver abscess in diabetic patients. Sci. Rep. 10 (1), 21329 (2020).","journal-title":"Sci. Rep."},{"issue":"7","key":"50136_CR24","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/nm.4345","volume":"23","author":"H Wu","year":"2017","unstructured":"Wu, H. et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat. Med. 23 (7), 850\u2013858 (2017).","journal-title":"Nat. Med."},{"issue":"5","key":"50136_CR25","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1080\/1061186X.2019.1681433","volume":"28","author":"G Chao","year":"2020","unstructured":"Chao, G. et al. Study on the characteristic of intestinal flora in patients with dual antiplatelet therapy. J. Drug Target. 28 (5), 500\u2013507 (2020).","journal-title":"J. Drug Target."},{"key":"50136_CR26","doi-asserted-by":"publisher","first-page":"635","DOI":"10.3389\/fendo.2020.00635","volume":"11","author":"M Yang","year":"2020","unstructured":"Yang, M. et al. Dapagliflozin Modulates the Fecal Microbiota in a Type 2 Diabetic Rat Model. Front. Endocrinol. (Lausanne). 11, 635 (2020).","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"2","key":"50136_CR27","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1136\/gut.48.2.260","volume":"48","author":"I Molle","year":"2001","unstructured":"Molle, I. et al. Increased risk and case fatality rate of pyogenic liver abscess in patients with liver cirrhosis: a nationwide study in Denmark. Gut 48 (2), 260\u2013263 (2001).","journal-title":"Gut"},{"issue":"3","key":"50136_CR28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.diabet.2019.01.008","volume":"45","author":"AJ Scheen","year":"2019","unstructured":"Scheen, A. J. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications. Diabetes Metab. 45 (3), 213\u2013223 (2019).","journal-title":"Diabetes Metab."},{"issue":"4","key":"50136_CR29","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1111\/dom.16198","volume":"27","author":"K Hirayama","year":"2025","unstructured":"Hirayama, K. et al. Effects of the SGLT2 inhibitor ipragliflozin and metformin on hepatic steatosis and liver fibrosis: Sub-analysis of a randomized controlled study. Diabetes Obes. Metab. 27 (4), 2059\u20132069 (2025).","journal-title":"Diabetes Obes. Metab."},{"key":"50136_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8111814","author":"F Iannantuoni","year":"2019","unstructured":"Iannantuoni, F. et al. The SGLT2 inhibitor Empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes.. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm8111814 (2019).","journal-title":"J. Clin. Med."},{"issue":"10","key":"50136_CR31","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1111\/dom.14488","volume":"23","author":"S Saffo","year":"2021","unstructured":"Saffo, S. et al. Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin. Diabetes Obes. Metab. 23 (10), 2402\u20132408 (2021).","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"50136_CR32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1001\/jama.1997.03550020017009","volume":"278","author":"SH Cheng","year":"1997","unstructured":"Cheng, S. H. & Chiang, T. L. The effect of universal health insurance on health care utilization in Taiwan. Results from a natural experiment. JAMA 278 (2), 89\u201393 (1997).","journal-title":"JAMA"},{"issue":"11","key":"50136_CR33","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.puhe.2006.06.011","volume":"120","author":"N Huang","year":"2006","unstructured":"Huang, N. et al. Trends in rural and urban differentials in incidence rates for ruptured appendicitis under the National Health Insurance in Taiwan. Public. Health. 120 (11), 1055\u20131063 (2006).","journal-title":"Public. Health"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50136-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50136-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50136-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T11:03:57Z","timestamp":1783076637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50136-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["50136"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-50136-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The NHIRD secures patients\u2019 personal data by employing encryption to safeguard privacy. It also provides researchers with anonymous identification numbers linked to relevant claims data, including gender, date of birth, medical services, and prescriptions. As a result, patient consent is not required to access the NHIRD for this research project. This research project received approval for exemption from the Institutional Review Board (IRB) at China Medical University (Approval Number CMUH110-REC3-133(CR-3)), and the IRB explicitly waived the requirement for informed consent. All procedures were conducted in accordance with the relevant guidelines and regulations, as well as the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors agree to publish the article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"20358"}}